Clinical Trials Pipeline & In-Development

GMA106

also known as: GMA-106

Gmax Biopharm's GLP-1 / FGF21 dual-activity candidate — Phase 2 in obesity and MASH; pairs GLP-1 appetite suppression with FGF21's metabolic and hepatic steatosis effects.

A dual-activity peptide combining GLP-1 receptor agonism with FGF21 analog activity, developed by Gmax Biopharm (Hangzhou, China), in Phase 2 for obesity and metabolic dysfunction-associated steatohepatitis (MASH); the combination pairs GLP-1 appetite and glycemic effects with FGF21's documented insulin-sensitization and hepatic-steatosis-reduction activity.

Mechanism of action

Combined GLP-1 receptor agonism and FGF21 receptor (FGFR1c/β-Klotho) agonism in a single molecule. FGF21 signaling drives hepatic fat oxidation, improves insulin sensitivity, and in FGF21-analog clinical trials (pegozafermin, efruxifermin) produces substantial reduction in liver steatosis — complementary to GLP-1 effects.

Primary uses

Obesity (Phase 2)
MASH/NASH (Phase 2)

Typical dosing

once weekly (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in China for obesity and MASH.

References

[manufacturer] Gmax Biopharm pipeline page — GMA106 GLP-1/FGF21 dual agonist.

Related peptides

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Pemvidutide

Altimmune's GLP-1 / glucagon co-agonist — received FDA Breakthrough Therapy Designation for MASH in January 2026 after positive IMPACT Phase 2b antifibrotic data, with Phase 3 initiation planned for 2026.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.